Fate Therapeutics, Inc.

NASDAQ:FATE

Biotechnology

Healthcare
$1.05 -0.00%

-$0.00 today

Market cap
$122.39M
Beta
2.52
P/E (TTM)
-1.8
EPS (TTM)
-$1.08
52W Low $0.91High $2.88

Volume 1.87M

Average 2.92M

FATE Income Before Tax

Profit after all operating and non-operating items but before income tax.

Fate Therapeutics, Inc.NASDAQ: FATE

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$31.21M, compared with -$37.62M a year earlier. Trailing-twelve-month income before tax was -$129.91M.

Context

  • Income before tax amounted to 2051.1% of revenue in FY2025, up 684.6 pp from a year earlier.
  • Income before tax grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$31.21M or moves back toward the trailing-twelve-month quarterly average of -$32.48M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$31.21M+3.6% QoQ
Last fiscal yearDec 2025
-$136.32M+26.8% YoY
LTMMar 2026
-$129.91M+26.1% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.0%——
1 year+26.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(136.32M) USD
Year-over-year change
+26.8%

Income Before Tax vs competitors

How FATE compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +26.1% is the 2nd highest of 10, against a peer median of +2.6%.
  • Income before tax amounts to 2056.8% of revenue for FATE, versus a peer median of 572.6%.
FATE Competitors
Income Before Tax for FATE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MOLNMolecular Partners AGLTM Mar 2026-CHF 72.05M CHF-17.4%——
PEPGPepGen Inc.LTM Mar 2026-$77.15M USD+24.9%——
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026-$77.8M USD+39.1%—465.3%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026-$84.53M USD-68.1%——
INOInovio Pharmaceuticals, Inc.LTM Mar 2026-$84.93M USD+12.0%——
NKTXNkarta, Inc.LTM Mar 2026-$99.93M USD+10.2%——
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026-$113.28M USD+2.6%——
ALECAlector, Inc.LTM Mar 2026-$125.22M USD-1.5%—679.9%
FATEFate Therapeutics, Inc.LTM Mar 2026-$129.91M USD+26.1%—2056.8%
VORVor Biopharma Inc.LTM Mar 2026-$883.08M USD-644.6%——
Peer median (excluding FATE) —+2.6%—572.6%

Competitors are the stored peer set for FATE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.85M96.3M63.53M13.63M6.65M
Cost of Revenue5.85M13.76M157.19M118.53M12.9M
Gross Profit50M82.54M(93.65M)(104.9M)(6.26M)
Gross Margin89.5%85.7%-147.4%-769.6%-94.1%
Research & Development215.52M320.45M172.6M135M107.83M
Selling, General & Admin57.32M84.23M96.86M90.64M46.52M
Operating Expenses266.99M390.93M96.86M105.38M141.45M
Depreciation & Amortization5.85M13.76M18.28M18.96M9.3M
EBITDA(206.3M)(267.96M)(142.65M)(176.58M)(127.02M)
EBITDA Margin-369.4%-278.3%-224.5%-1295.4%-1911.2%
Operating Income(216.99M)(308.39M)(190.51M)(210.28M)(147.7M)
Operating Margin-388.6%-320.2%-299.9%-1542.6%-2222.4%
Interest Income1.31M5.84M17.19M17.29M11.05M
Interest Expense00000
Other Income / Expenses4.84M26.67M29.58M24.01M11.39M
Income Before Tax(212.15M)(281.72M)(160.93M)(186.26M)(136.32M)
Pre-Tax Margin-379.9%-292.5%-253.3%-1366.5%-2051.1%
Income Tax Expense00000
Net Income(212.15M)(281.72M)(160.93M)(186.26M)(136.32M)
Net Margin-379.9%-292.5%-253.3%-1366.5%-2051.1%
EPS (Basic)(2.24)(2.91)(1.64)(1.64)(1.15)
EPS (Diluted)(2.24)(2.91)(1.64)(1.64)(1.15)
Weighted Avg Shares94.75M96.83M98.41M113.69M118.79M
Weighted Avg Shares (Diluted)94.75M96.83M98.41M113.69M118.79M

Fate Therapeutics, Inc.

NASDAQ:FATE

Intrinsic Alpha fair value

Locked

Current Price

$1.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.